| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 83.5 | 8.2 |
| Net income | 58.1 | -15.8 |
| EPS (diluted, $ a share) | $0.80 | $-0.25 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +924.7% |
|---|---|
| Operating margin | 67.8% |
10-Q filed with the SEC, NASDAQ: FHTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Foghorn Therapeutics Inc.: key numbers
- Share price
- $1.83Close, Nov 17
- Market cap
- $110M
- Shares outstanding
- 59.96MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Foghorn Therapeutics Inc.
All →Foghorn Therapeutics Financial Results
Foghorn Therapeutics reported Q3 2026 financial results, highlighted by a significant increase in collaboration revenue to $83.5 million due to a cumulative catch-up adjustment. The company reported a net income of $44.5 million for the quarter and maintains a cash runway into the second half of 2029 to support its oncology and immunology pipelines.
“Our focus is on advancing our wholly owned portfolio, including our novel, oral I&I program in IBD, with potential for first-in-human trials by the end of 2027, and our Selective EP300 degrader which has an IND targeted for next year. We are also advancing a novel induced-proximity approach with the potential to deliver antibody-like efficacy against high-value secreted and transmembrane proteins through small molecules. With cash runway into the second half of 2029, we are well positioned to deliver on this strategy.”
Adrian Gottschalk, President and Chief Executive Officer
Foghorn Therapeutics Other 8-K Filing
Foghorn Therapeutics and Eli Lilly have decided to discontinue the clinical development of FHD-909 and their SMARCA2 degrader collaboration following a review of Phase 1 data. Consequently, Foghorn is implementing a strategic reprioritization and a 40% workforce reduction to extend its cash runway into the second half of 2029, incurring approximately $2.3 million in severance-related charges.
- Counterparty
- Eli Lilly and Company